Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ganirelix Acetate

FDA-approved product (injectable, injection), marketed as Fyremadel, Ganirelix Acetate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ganirelix Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Female infertility
  • Positive regulation of ovulation
  • Reproductive Techniques, Assisted

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Anti-gonadotropin-releasing hormones
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA69.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ganirelix Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ganirelix Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Novel Approach to Endometrial Preparation in Recipients of Donor Eggs

    NCT01424618 · start 2006-01

    Registered record
    Registry ID
    NCT01424618
    Conditions
    Implantation, Embryo
    Interventions
    Leuprolide; Ganirelix
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2006-01
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImplantation, Embryo
    InterventionLeuprolide; Ganirelix
    PhaseNot applicable
    Registry statusUnknown

  • Comparison of the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation

    NCT00417183 · start 2005-09

    Registered record
    Registry ID
    NCT00417183
    Conditions
    Infertility
    Interventions
    Arvekap 0.1 mg (Triptorelin, Ipsen, France); Ganirelix 0.25 (Orgalutran, Organon, The Netherlands)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2005-09
    Completion
    2007-06
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionArvekap 0.1 mg (Triptorelin, Ipsen, France); Ganirelix 0.25 (Orgalutran, Organon, The Netherlands)
    PhasePhase 4
    Registry statusUnknown

  • Administration of GnRH Antagonist to Oocyte Donation Recipients

    NCT00635258 · start 2004-01

    Registered record
    Registry ID
    NCT00635258
    Conditions
    Pregnancy; Embryo Implantation
    Interventions
    triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain); GnRH antagonist (Orgalutran®)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2004-01
    Completion
    2007-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPregnancy; Embryo Implantation
    Interventiontriptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain); GnRH antagonist (Orgalutran®)
    PhaseNot recorded
    Registry statusCompleted

  • Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients

    NCT00417144 · start 2003-11

    Registered record
    Registry ID
    NCT00417144
    Conditions
    Polycystic Ovary Syndrome; Ovarian Hyperstimulation Syndrome
    Interventions
    Arvekap 0.1mg (Triptorelin, Ipsen, France); Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2003-11
    Completion
    2007-05
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovary Syndrome; Ovarian Hyperstimulation Syndrome
    InterventionArvekap 0.1mg (Triptorelin, Ipsen, France); Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
    PhasePhase 4
    Registry statusUnknown

  • A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation

    NCT00298025 · start 2003-09

    Registered record
    Registry ID
    NCT00298025
    Conditions
    Infertile Women Undergoing Assisted Reproductive Technology (ART)
    Interventions
    Cetrotide®; Antagon ™; Recombinant human follicle stimulating hormone (r-hFSH); Human Menopausal Gonadotropin (hMG); Recombinant Human Choriogonadotropin (r-hCG)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-09
    Completion
    2004-05
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertile Women Undergoing Assisted Reproductive Technology (ART)
    InterventionCetrotide®; Antagon ™; Recombinant human follicle stimulating hormone (r-hFSH); Human Menopausal Gonadotropin (hMG) +1 more
    PhasePhase 4
    Registry statusCompleted